Optimizing the Use of BTK Inhibitors in B-Cell Malignancies: Insights for the Multidisciplinary Team

These downloadable slides from our live meeting series on BTK inhibitors review the current clinical rationale and most recent data on the use of ibrutinib and acalabrutinib for patients with MCL, CLL, or WM.
Christopher R. Flowers, MD, MS
Program Director
Andrew D. Zelenetz, MD, PhD
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 2.32 MB
Released: September 10, 2018

Acknowledgements

Jointly provided by the Purdue University and Clinical Care Options, LLC
Purdue University Logo

Accreditation: Dawn Sinclair, Purdue University sinclaid@purdue.edu
Certificates/Credits: Heather Holley, Purdue University hholley@purdue.edu

This activity is supported by an educational grant from
AstraZeneca

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Renier J. Brentjens, MD, PhD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

Downloadable slides on most current clinical data on frontline therapies for CLL.

Jeremy S. Abramson, MD, MMSc Released: December 3, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue